Emerald Mutual Fund Advisers Trust Sells 56,438 Shares of LivaNova PLC (NASDAQ:LIVN)

Emerald Mutual Fund Advisers Trust decreased its position in LivaNova PLC (NASDAQ:LIVN) by 10.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 471,674 shares of the company’s stock after selling 56,438 shares during the quarter. LivaNova accounts for 1.3% of Emerald Mutual Fund Advisers Trust’s portfolio, making the stock its 19th largest position. Emerald Mutual Fund Advisers Trust owned about 0.87% of LivaNova worth $21,843,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Russell Investments Group Ltd. increased its stake in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares in the last quarter. Sterling Capital Management LLC boosted its stake in LivaNova by 800.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after purchasing an additional 1,441 shares during the period. Central Pacific Bank Trust Division grew its stake in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after acquiring an additional 720 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in shares of LivaNova during the third quarter valued at about $219,000. Finally, Vestcor Inc bought a new stake in LivaNova in the 4th quarter worth approximately $204,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Up 0.7 %

Shares of NASDAQ LIVN opened at $37.51 on Tuesday. The stock has a market cap of $2.04 billion, a PE ratio of 89.31 and a beta of 0.90. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $64.48. The business has a 50-day moving average price of $38.74 and a 200 day moving average price of $45.99. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 25th. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. The Goldman Sachs Group reduced their target price on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. Finally, Barclays cut their price target on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.